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Abstract Study Design A broad narrative review.
Objective Management of spinal disorders is continuously evolving, with new
technologies being constantly developed. Regardless, assessment of patient outcomes
is key in understanding the safety and efﬁcacy of various therapeutic interventions. As
such, evidence-based spine care is an essential component to the armamentarium of the
spine specialist in an effort to critically analyze the reported literature and execute
studies in an effort to improve patient care and change clinical practice. The following
article, part one of a two-part series, is meant to bring attention to the pros and cons of
various study designs, their methodological issues, as well as statistical considerations.
Methods An extensive review of the peer-reviewed literature was performed,
irrespective of language of publication, addressing study designs and their methodolo-
gies as well as statistical concepts.
Results Numerous articles and concepts addressing study designs and their method-
ological considerations as well as statistical analytical concepts have been reported.
Their applications in the context of spine-related conditions and disorders were noted.
Conclusion Understanding the fundamental principles of study designs and their
methodological considerations as well as statistical analyses can further advance and
improve future spine-related research.
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Introduction
Outcome assessment is one of the most important features of
evidence-based medicine, which has been deﬁned as “the
conscientious, explicit and judicious use of current best evidence
in making decisions about the care of individual patients” and
therefore depends on accurate description of outcomes.1 Due to
the enormous increases in health care expenditure, numerous
health policy makers and regulators have introduced evidence-
basedmedicine and the proof of cost-effectiveness into both the
clinical and reimbursement guidelines.
Outcome assessment can be performed for several rea-
sons: to trace the progress of an individual patient, to study
the efﬁcacy of a treatment method, to compare the effective-
ness of different treatments, or to evaluate the cost-effective-
ness of different treatments. In technical terms, outcome
assessment aims at establishing four parameters: efﬁcacy
(can it work?), effectiveness (does it work?), efﬁciency
(does it produce value?), and safety (do adverse events exist
and are they acceptable?). Due to the plethora of innovative
spine technologies and the changing face of the management
of spinal disorders, understanding outcome assessment is
critical to judge the efﬁcacy and safety of a treatment and, in
so doing, further advance the ﬁeld. As such, the following
article, part one of a two-part series, describes the rationale of
outcome assessment followed by a fundamental description
of study designs, methodologies, and analyses while focusing
on spinal disorders.
Study Designs
Deﬁning End Points
The ﬁrst andmost important step in any outcome assessment is
to clearly deﬁne the outcome(s) of interest and the scale of
measurement. Preferably, this deﬁnition will also include an
inﬂuential variable or a risk factor that allows formulation of a
study question. Unfortunately, more often than not, studies are
initiated to research issues such as “We want to look at the
clinical advantage of implantXover implant Y”—and,more often
thannot, such studies fail because they inadequately deﬁnewhat
tomeasure andhow tomeasure it. Instead, a good startmight be
to ask, “Are there differences in the 5-year rates of radiologic
signs of adjacent segment degeneration of implant X versus
implant Y in patient population Z?” Such a clearly formulated
questionwill bemost helpful in choosing the right type of study
design, theappropriate statistical analysis, and the interpretation
of the ﬁndings in relation to the study question and will even
facilitate writing the manuscript.
Study Design Types
Twomain study types exist, observational and experimental/
interventional, depending onwhether the investigator mere-
ly observes events unfold or whether he or she intervenes to
assess the effectiveness of a treatment in a controlled setting
comparing groups that were established at baseline in a
certain manner (e.g., randomized controlled trial [RCT]).
Further characterization depends on several factors, such as
the chronology of outcome occurrence and assessment (pro-
spective/retrospective), the number of interventions/groups
(controlled studies/longitudinal cohorts and case series), or
patient allocation (randomized/matched/nonrandomized).
When choosing from these options, the two most important
questions to answer are “Is this study design able to show
what I want to see?” or in scientiﬁc terminology “Is this
design valid?” and—given the constraints in funding and time
available, equally important—“Is this design cost-effective to
show what I want to see?” It has been recognized that the
main antagonist of validity is bias, which is deﬁned as a
“systematic deviation from the truth,” usually because of a
ﬂaw in study design. The probability of biased results in any
given study depends on the rigor of its design. The categori-
zation into various “levels of evidence” depends on factors
such as study design and objective (e.g., diagnostic, prognos-
tic, therapeutic, among others), with level I studies being
regarded as those with the highest degree of evidence and
those less likely to be affected by bias (►Table 1).
Creation of high-level evidence study designs is desirable
for several reasons: they produce the “best evidence” desired
for evidence-based medicine, they hold the prospect of the
highest return on investment, and they are more likely to get
published.2,3 However, as pointed out previously, cost-effec-
tiveness is another important aspect. A phase III study (which
is the postapproval, postmarketing study of Food and Drug
Administration–approved drugs and interventions) does not
necessarily need to be randomized or controlled to advance
insight. For example, it does not matter if a speciﬁc drug or
device is more or less effective than Vioxx (rofecoxib) or a
metal bearing hip like the SR hip, because in both cases the
respective manufacturers have withdrawn the drug or re-
called the device in question.
In summary, choosing a valid and cost-effective study
design will help in obtaining funding for a study, conducting
the project, and publishing the ﬁndings. Although case re-
ports, case series, and cross-sectional and observational
studies are the most common studies published in the spine
literature, there has been a steady rise in RCTs and systematic
reviews/meta-analyses throughout the past decade.4 Next,
the most common study designs are presented in reverse
level-of-evidence hierarchy, and their advantages and disad-
vantages are further illustrated in ►Table 2.
Cross-Sectional Studies, Case Series, and Case Reports—
Level IV
Cross-sectional studies, case series, and case reports are obser-
vational studies. A cross-sectional study can be considered a
survey that is used to gather information about a population at a
single point in time. With its propensity to determine preva-
lence, risk factors, and outcomes, a cross-sectional study can
attempt to draw a relationship between factors of interest. An
inherent limitation lies in the foundational circumstance that
factors of interest and outcomes are both measured at the same
time. Subsequently, the interpretation of the results from cross-
sectional studies are complicated by not understanding the
causal pathway of events, meaning that one cannot be sure
which came ﬁrst, the “risk factor” or the “outcome.” Case series
and case reports are often used to describe or report unusual
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events in a small group of patients but offer little information
regarding generalizations about the speciﬁc treatments, com-
parisons between groups are not possible, and assessing the
outcomes and drawing conclusions based on small sample size
are far-stretched. However, such study designs may provide
important anecdotal information that lead to future investiga-
tions. For example, a recent case series addressing the proof-of-
concept principle that magnetically controlled growing rods for
the treatment of early onset scoliosis has provided newdirection
for the treatment of young children with severe deformities by
eliminating the need of frequent surgeries and potential com-
plications associated with traditional rod distraction.5 Observa-
tional studies are also useful to document clinically meaningful
yet unexpected outcomes, such as adverse effects after spinal
treatments.
Case-Control Study—Level III
This study type begins by identifying a group of individuals
with an outcome of interest (cases) and a group of individuals
without the outcome of interest (controls). However, it is
crucial that other than for the outcome being investigated,
these groups are as similar as possible (i.e., that controls could
Table 1 Study types and levels of evidence for primary research questions
Level Types of studies
Therapeutic studies:
investigating the re-
sults of treatment
Prognostic studies:
investigating the ef-
fect of a patient
characteristic on the
outcome of disease
Diagnostic studies:
investigating a diag-
nostic test
Economic and deci-
sion analyses: devel-
oping an economic or
decision model
I • High-quality RCT
with statistically sig-
niﬁcant difference
or no statistically
signiﬁcant differ-
ence but narrow
conﬁdence intervals
• Systematic reviewa,b
of level I RCTs
(studies were
homogeneous)
• High-quality pro-
spective studyc (all
patients were en-
rolled at the same
point in their disease
with80% follow-up
of enrolled patients)
• Systematic reviewa,b
of level I studies
• Testing of previously
developed diagnos-
tic criteria in series
of consecutive pa-
tients (with univer-
sally applied
reference gold stan-
dard)
• Systematic reviewa,b
of level I studies
• Sensible costs and
alternatives; values
obtained from many
studies; multiway
sensitivity analyses
• Systematic reviewa,b
of level I studies
II • Lesser-quality RCT
(e.g., <80% follow-
up, no blinding, or
improper randomi-
zation)
• Prospectivec com-
parative studyd
• Systematic reviewa,b
of level II studies or
level I studies with
inconsistent results
• Retrospectivef study
• Untreated controls
from an RCT
• Lesser-quality pro-
spective studyc
(e.g., patients en-
rolled at different
points in their dis-
ease or<80% follow-
up)
• Systematic reviewa,b
of level II studies
• Development of di-
agnostic criteria on
basis of consecutive
patients (with uni-
versally applied ref-
erence gold
standard)
• Systematic reviewa,b
of level II studies
• Sensible costs and
alternatives; values
obtained from limit-
ed studies; multiway
sensitivity analyses
• Systematic reviewa,b
of level II studies
III • Case control studye
• Retrospectivef com-
parative studyd
• Systematic reviewa,b
of level III studies
• Case control studye • Study of nonconsec-
utive patients (with-
out consistently
applied reference
gold standard)
• Systematic reviewa,b
of Level-III studies
• Analyses based on
limited alternatives
and costs; poor es-
timates
• Systematic reviewa,b
of level III studies
IV Case seriesg • Case seriesg • Case-control studye
• Poor reference
standard
• No sensitivity
analyses
V Expert opinion • Expert opinion • Expert opinion • Expert opinion
Abbreviation: RCT, randomized controlled trial.
Source: Adapted from material published by the Centre for Evidence-Based Medicine. For more information, please see www.cebm.net.
aA complete assessment of the quality of individual studies requires critical appraisal of all aspects of the study design.
bA combination of results from two or more prior studies.
cStudy was started before the ﬁrst patient enrolled.
dPatients treated one way compared with patients treated another way.
ePatients identiﬁed for the study on the basis of their outcome, called cases, are compared with those who did not have the outcome, called controls.
fStudy was started after the ﬁrst patient enrolled.
gPatients treated one way with no comparison group of patients treated another way.
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Table 2 Main types of quantitative research designs and their associated advantages and disadvantages
Type of study design Advantages Disadvantages
RCT (parallel design) • In well-constructed study, un-
biased distribution of con-
founds
• Blindness of assessment
• Can provide temporal sequence
of events
• Statistical analyses facilitated by
randomization
• The ethical issue of who receives
a speciﬁc treatment and if that
treatment can possibly do more
harm than good
• Designs costly and time-con-
suming
• Compliance issues or partici-
pants lost to follow-up may oc-
cur, which affects validity
• Randomization techniques may
be faulty; however, established
methods could account for
proper randomization of pa-
tients
• Through time, contamination
between groups may occur and
should be accounted for
• Biases (preallocation, selection,
performance, detection, exclu-
sion, publication)
RCT (crossover design) • All subjects receive treatment
and serve as own controls
• Error variance reduced and
sample size needed is reduced
• Blinding may exist
• All subjects receive placebo or
alternative treatment at some
point
• Unknown or lengthy washout
period
• Not applicable in treatments
that are associated with per-
manent effects
Cohort study • Determines the incidence of
developing the disease in both
types of groups
• Confounders can be evaluated
and their inﬂuence upon the
outcome can be determine
• Can evaluate various outcomes,
detect associations, analyze
time relationships, monitor
changes over time, and assess
rare and unique exposures
• Can establish the relations be-
tween antecedent events and
outcomes
• Compared with RCT, less ex-
pensive and easier
administration
• Can be time-consuming (if pro-
spective in nature, but retro-
spective cohort designs may
reduce time and subsequent
costs)
• Difﬁcult to follow the original
sample group through time
• Blinding is difﬁcult and ran-
domization not present
• Poor sample sizes and short
follow-up for rare diseases
• Various hidden confounding
variables may affect outcome
Case-control study • Beneﬁcial in studying rare dis-
eases or diseases with long du-
ration to develop outcome
• Retrospective and thus inex-
pensive and quick studies to
conduct if time is an issue
• Obtaining an adequate repre-
sentative control group may be
difﬁcult
• Sampling bias may exist where
deﬁning a homogenous disease
group as well as control group
could be problematic and con-
tain confounds
• Demographics of the groups in
question may prevent general-
izing results and increasing ex-
ternal validity
• How subjects are recruited may
be questionable
• Obtaining data to determine
exposure may be difﬁcult and
prove challenging/time-con-
suming
(Continued)
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become cases once they show the relevant end point). Data is
collected regarding risk factors or exposures that may have
contributed to the outcome of interest, and the resultant
differences between the cases and controls are compared.
Case control studies are attractive because they are simple
and inexpensive to perform. This design is particularly inter-
esting for rare or late-onset outcomes, which would make a
prospective study prohibitively complex and expensive, as
very large numbers of patients would have to be followed for
an extended period of time.
Cohort Study (as a Comparative Prospective Study)—Level II
A cohort study seeks to identify a group of individuals with a
risk factor of interest and another group of individuals
without this risk factor and follows them over a prespeciﬁed
period of time while measuring/counting the occurrence of
outcomes of interest per group. Such a study can detect
associations, analyze time relationships, monitor changes
over time, and assess rare and unique exposures. The
strength of such a research design lies in its ability to
establish associations between antecedent events and sub-
sequent outcomes, and a timeline of events is established.
Cost, resource availability, and practicality of sustaining the
study goals over time are important considerations prefera-
bly made a priori.
Randomized Controlled Study—Level I
RCTs are prospectively conducted and are either short-term
(i.e., end points are assessed immediate postintervention) or
longitudinal (i.e., end points are assessed at several months or
years from intervention). The participants are randomized,
which is deﬁned by an unpredictable allocation of individuals
to the treatment groups, thereby distributing equally any
preexisting factors and biases or confounders that can poten-
tially affect the outcome of interest. Typically, the baseline
characteristics of the control and experimental arms should
be the same before the trial starts to ensure that differences
observed between the two groups at the end of the trial are
attributable to the treatment or intervention administered
during the study. The two principle subtypes of RCTs are the
crossover and parallel designs. The parallel design has two
independent experimental arms, usually deﬁned as a control
arm and an interventional arm. Two different treatments are
administered, the groups are followed for a period of time,
Table 2 (Continued)
Type of study design Advantages Disadvantages
• Due to the retrospective nature
of the study, establishing a
timeline when events occurred
that may have contributed to
the outcome is difﬁcult, thus,
obtaining consistent values of
timing of events for both
groups may not be probable
• The study controls are selected
from the investigator and can
entail sampling bias, thus are
not representative of the pop-
ulation as a whole and risk ratios
cannot be analyzed
• Recall bias by the participants
may be present and dilute the
validity of the results
• Hidden confounders
Cross-sectional survey • Inexpensive
• Simple
• Ethically sound
•Does not establish causality, but
possible association
• Potential for recall bias
• Confounders unequally distrib-
uted
• Unequal group sizes
Case series and case reports • May provide insightful infor-
mation into an area for further
investigation
• Provides insight for very rare
diseases and their management
• Multiple and nonexistence of
comparison group
Abbreviation: RCT, randomized controlled trial.
Source: Adapted from Samartzis D, Dominique DA, Perez-Cruet MJ, et al. Clinical outcome analyses. In: Perez-Cruet MJ, Khoo LT, Fessler RG, eds. An
Anatomical Approach to Minimally Invasive Spine Surgery. St. Louis, MO: Quality Medical Publishing, Inc.; 2006:103–130.
Global Spine Journal Vol. 5 No. 2/2015
Clinical Outcomes Assessment for Spinal Disorders Vavken et al.160
Th
is
 d
oc
um
en
t w
as
 d
ow
nl
oa
de
d 
fo
r p
er
so
na
l u
se
 o
nl
y.
 U
na
ut
ho
riz
ed
 d
ist
rib
ut
io
n 
is 
st
ric
tly
 p
ro
hi
bi
te
d.
and their outcomes are recorded. The group allocation is
maintained for the duration of the study. By comparison, a
crossover design represents two paired groups that receive
the same treatment at one point or another, but at alternating
times. In the crossover design, themain goal is tomeasure the
treatment effect and determine whether a sequential or
period effect exists. A crossover RCT is associated with con-
cerns regarding any residual or carryover effects derived from
the previous treatment. If these concerns are an issue, a
washout period may be incorporated to minimize the effects
of the previous treatment. Crossover designs usually do not
lend themselves to surgical studies.
Systematic Reviews and Meta-Analyses—Levels I to III
A systematic review entails the systematic collection of data
without formal mathematical processing or pooling of data. A
meta-analysis is the “quantitative synthesis” or fusion of data to
determine the effect size of the intervention across studies, if
sufﬁcient data can be found in the systematic review and if the
data is homogeneous enough (bothmathematically and clinical-
ly sensible) to allow such a fusion. The intention is to determine
the quality of evidence and the effect size of the treatment.6
Depending on the origin and quality of the primary data,
systematic reviews/meta-analyses are regarded as level I to level
III studies. The advantage of systematic reviews/meta-analyses,
or a study of studies rather than a study of patients, is that it
incorporatesmany patients often from large and diverse sample
sources, different cultures, and countries/facilities in ways that
cannot be approximated in a single-site study. Their obvious
weakness is that they are only as good as their primary study
sources and their reporting as systematic reviews/meta-analyses
are data processing and not data generating.
Study Methodologies, Implementation and Analyses
After deﬁning a study question of interest and choosing a
valid and cost-effective design, the next problem that
presents itself to the researcher is implementation—how to
conduct a study. Fortunately, a helpful network of guidelines
exist on how to conduct and report a study, such as the
CONSORT statement for RCTs,7 the STROBE panel for case
control and cohort studies,8 and the PRISMA statement for
meta-analyses.9 Also, several highly ranked journals require
the use of these tools as a prerequisite for publication.
However, a few issues crucial to the quality of a study deserve
detailed mentioning.
Power and Sample Size
Statistical power has been one of the most neglected issues in
clinical research.10,11 Understanding statistical power is
based on awareness of type I (i.e., false-positive) and type II
(i.e., false-negative) errors. Type I error is expressed in form of
the p value (or the α value), which can be calculated appro-
priately and without loss of validity at the end of a study.
However, type II error has to be considered at the beginning of
a study and cannot be addressed during the analysis stage. A
power analysis shows how likely a study is to fall into the type
II error trap; therefore, the greater the sample size, the higher
the power of a study.12,13
Power can be thought of as a visibility problem—“If I
want to see something very, very small I need a strong
microscope, but if I want to see something very big I don’t
even need my glasses.” In this metaphor, the size of the
object is the anticipated effect size, the strong microscope
is a large study, and the naked eye a small one. Hence,
before the beginning of a study, an effect size (i.e., mean
difference between fusion rates, risk of developing a spinal
complication) has to be chosen as well as the appropriate
type of microscope (i.e., study design and sample size) to
help understand the power of a study. Choosing an effect
size has to strike a balance between scientiﬁc rigor, clinical
meaning, and cost, leading to a study that is able to show a
scientiﬁcally important and clinically relevant difference
without being prohibitively large. The second crucial pa-
rameter in addition to sample size is variance (e.g., stan-
dard deviation). An outcome with a high variance may
imply that the precision around the effect size may be
diminished and not as robust. Power may be achieved by
the sample size at the end of the study (i.e., patients
available for analysis), not at the beginning of the study
(i.e., patients enrolled); as such, it makes sense to measure
and account for attrition, usually by increasing the calcu-
lated required sample size.13 However, if ample a priori
evidence exists in the literature regarding effect sizes and
their variation, one can estimate the sample size needed
based on a predetermined chosen power threshold before
the onset of a study, in particular if the study design is an
RCT.
Intention to Treat and Per Protocol Analysis
For most clinical studies, follow-up is a critical; however, it is
often elusive and patients are often lost to follow-up, and still
others are not compliant with treatment. Some patients miss
follow-up appointments or the documentation is incomplete.
At the end of a study, there are always some patients who did
not receive the treatment they were supposed to receive or
were not followed sufﬁciently and the question remains
whether or not, for all the inconsistencies, to exclude them
from the analysis. An example is the often excessive amount
of dropout/withdrawal rates seen in RCTs comparing cervical
disk arthroplasty to that of anterior cervical diskectomy and
fusion cases, whereby such effects render the groups practi-
cally noncomparable at follow-up.14 Analysis after exclusion
of such patients is called per protocol, because only patients
who completed the protocol are considered and will produce
an estimate of efﬁcacy (what a treatment can do). Including
all patients into the ﬁnal analysis, regardless of their compli-
ance, is called intention to treat analysis and will produce a
clinically more realistic estimate, referred to as effectiveness
(what a treatment actually does), which has usually a smaller
effect size and a larger p value than a per protocol analysis.
Allocation Concealment and Blinding
A crucial point that unfortunately was not included in the
term randomized controlled trial is blinding or concealed
allocation. Preferably, allocation (i.e., group assignment) is
concealed from both patients and outcome assessors because
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of the risk of inﬂuencing study outcomes (both willingly and
subconsciously) based on the allocation. In surgical studies,
concealed allocation is not always possible, especially when
different surgical treatments or surgical and nonsurgical
treatments are compared. However, outcome assessment
can be often partially blinded (e.g., radiologic end points
but not clinical exam), and sham operations have gained
increasingly positive resonance as a method to minimize
confounding factors of conventional prospective comparative
study protocols (i.e., surgery devoid of a therapeutic step).
Confounding and Bias
Two important problems that arguably do not receive the
attention they deserve are bias and confounding. Bias is the
systematic deviation from the truth, asmentioned previously,
and is usually caused byﬂawed study design. It can be avoided
by diligent study conduct, but it cannot be ruled out, and its
impact cannot be assessed. A confounding variable presents
when there is a causal association between an exposure and
an outcome to a varying degree based upon a third variable
(the confounder). Fortunately, confounding can be tested and
Fig. 1 Flow chart demonstrating appropriate statistical analyses tests when the values are numerical (continuous) or ordinal. (Adapted from
Petrie A. Statistics in orthopaedic papers. J Bone Joint Surg Br 2006;88(9):1121–1136.18) Abbreviation: ANOVA, analysis of variance.
Fig. 2 Flow chart demonstrating appropriate statistical analyses tests when the values are binary. (Adapted from Petrie A. Statistics in
orthopaedic papers. J Bone Joint Surg Br 2006;88(9):1121–1136.18)
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accounted for by including the confounding variable into the
statistical analysis, such as by stratifying patients by their
confounding status. In spine surgery, important examples of
confounding include the effect of anesthetic medication or
age on the interpretation of motor evoked potentials during
pediatric spine surgery,15,16 or the differential use of steroids
in the medical treatment of a spinal cord injury with ganglio-
side GM1 or growth factors.17
Statistical Considerations
Statistical analysis of study results can be a daunting task, and
seeking professional help from an individual with training in
biostatistics is encouraged for all studies. However, in contrast
to the complex, detailed methods, the rationale for statistical
analysis is very straightforward. Two types of analysis can be
distinguished: descriptive statistics and statistical inference.
Descriptive statistics, as the name implies, give a systematic
account of what was observed in a study. Statistical inference
tries to put ﬁndings into relation and searches for associations
between variables by formulating a hypothesis and using
appropriate tests to prove or refute it.
Choosing the appropriate descriptive statistic and test
depends on the type of variable used: binary (pain or no
pain), categorical (e.g., disk bulge, extrusion, sequestered),
ordinal (e.g., functional disability or lifestyle scores), or
continuous/numerical (e.g., estimated blood loss, pain
scores; ►Figs. 1 and 2).18,19 The usual rationale behind
statistical assessment is testing for superiority, present if
one group is better than the other. However, recent develop-
ments in scientiﬁc methodology have come to emphasize
noninferiority and equivalence. Brieﬂy, such studies try to
show that two interventions/groups have substantively the
same outcome (equivalence) or one intervention/group is no
worse within a margin (noninferiority). There are two good
reasons to consider such designs. First, if a current gold
standard treatment exist, it is unethical to not use it in a
comparative study—a situationwhere it is advantageous to be
able to show no worse within a margin. Second, most ortho-
pedic treatments already have very good and excellent pri-
mary outcomes (e.g., single-level anterior cervical fusions)
and leave only little room for improvement. However, a new
technique could be superior in the secondary outcomes,
safety, or cost-effectiveness—a situation where demonstrat-
ing that primary outcomes are substantively the same allows
for comparison of such further outcomes.
Conclusion
Spine-related disorders are some of the most disabling con-
ditions worldwide.20 The prevalence of such disorders con-
tinues to rise and the management options continue to
evolve. The assessment of the safety and efﬁcacy of various
therapeutic interventions or understanding of the natural
course of disease is imperative to improve clinical decision
making and take measures to enhance patient outcomes. For
the ﬁeld to progress and develop novel technologies to
improve patient quality of life or establish preventative
models, understanding study designs, their methodologies,
and analytical considerations is imperative.
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